Akeso and Summit Therapeutics have shared the full data from the HARMONi-6 trial of PD-1xVEGF bispecific ivonescimab as a ...

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced CRC and KRAS G12D Inhibitor in Advanced ...

Ivonescimab’s progression-free survival data in non-small cell lung cancer bode well for an upcoming overall survival readout ...

RATIONALE-307 and -312 – reinforce the PD-1 inhibitor’s proven clinical benefit in both NSCLC and ES-SCLCEarly data from investigational HPK1 inhibitor BGB-26808, in combination with TEVIMBRA, show ...

The poster for INSIGHT-003 and the Trial in Progress ePoster for TACTI-004 can be found at the Posters & Publications section of Immutep’s website.

A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study ...

Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...

Summit Therapeutics (Nasdaq: SMMT) said it plans to file a biologics license application in the fourth quarter for ...

NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell DeathData Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) -- ...

Approved targeted drugs for HER2 -mutant NSCLC include trastuzumab deruxtecan (T-DXd, Enhertu) -- which is highly effective ...

In the current study, the association between mRNA COVID vaccination and survival was strongest among patients whose tumors ...